WO2004096860A1 - 目的蛋白質の製造方法、融合蛋白質及びその遺伝子、インテインの部分配列蛋白質及びその遺伝子、発現ベクター、並びに形質転換体 - Google Patents
目的蛋白質の製造方法、融合蛋白質及びその遺伝子、インテインの部分配列蛋白質及びその遺伝子、発現ベクター、並びに形質転換体 Download PDFInfo
- Publication number
- WO2004096860A1 WO2004096860A1 PCT/JP2004/006191 JP2004006191W WO2004096860A1 WO 2004096860 A1 WO2004096860 A1 WO 2004096860A1 JP 2004006191 W JP2004006191 W JP 2004006191W WO 2004096860 A1 WO2004096860 A1 WO 2004096860A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- fusion protein
- intin
- target protein
- peptide bond
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain
Definitions
- the present invention relates to a method for producing a target protein, a fusion protein and its gene, a partial distribution protein of intin and its gene, an expression vector, and a transformant. More specifically, the present invention relates to a method for producing a target protein by excising a target protein from a fusion protein of a molecular chaperone and an intervening protein having peptide bond cleavage activity and the target protein by the action of the intervening protein, the fusion protein and the fusion protein
- the present invention relates to a gene, an intin partial sequence protein having peptide bond cleavage activity, a gene thereof, an expression vector, and a transformant. According to the present invention, a target protein can be efficiently obtained as a normal protein even if it is a protein that is difficult to be expressed by ordinary gene recombination techniques. Background art
- the expressed target protein may not be properly folded, and the target protein may not be obtained as an abnormal protein having an incorrect three-dimensional structure.
- abnormal proteins often form insoluble aggregates called inclusion bodies. Then, it is very difficult to refold the abnormal protein that has once become an inclusion body to become a normal protein, and it is often unsuccessful.
- the target protein can be combined with glutathione-S-transferase (GST), thioredoxin, maltose binding protein, etc.
- GST glutathione-S-transferase
- thioredoxin thioredoxin binding protein
- a method for expressing the protein as a fusion protein has been proposed. With this method, it is difficult to eliminate the formation of inclusion bodies with high efficiency (for example, Smith, DB, et al., Gene, 1988, Vol.
- a target protein as a normal protein having a correct three-dimensional structure by the action of a molecular chaperone, which is a protein that supports a protein folding reaction.
- a molecular chaperone which is a protein that supports a protein folding reaction.
- a target protein is co-expressed with a molecular chaperone in a host, and the target protein is expressed as a normal protein by the action of the molecular chaperone.
- the amount of the target protein obtained as a normal protein has not been drastically increased (Nishihara et al., Applied and Enviromental Mental Bio Mouth Sea. ⁇ Applieaande nv iro nme ntal mi crobiology), 1998, Vol. 64, p. 1694—1699).
- a porphyrin ninsubunit linking body in which subunits of chaperonin, a kind of molecular chaperone, are connected to each other. That is, a target protein is produced and used as a fusion protein with a linked Shanin nin subunit in which 1 to 20 Shanin nin subunits are connected in series. At this time, the target protein is stored inside the solid structure of shanin as well as forming a complex with natural shanin. As a result, the target protein is easily obtained as a correctly folded normal protein, and the formation of inclusion bodies can be suppressed.
- the target protein can be protected from attack by a host-derived protease (see WO02Z052029 A1). That is, according to this method, it is possible to express various viruses, various antibodies, seven-transmembrane receptors (G protein-coupled receptors), cytokines, and the like, which have toxicity to the host. In this method, it is necessary to excise the target protein from the S-mating protein as in the conventional method used for fusion proteins such as GST, thioredoxin, and maltose binding protein.
- the target protein is cut out by allowing a limited-degraded protease to act on the fusion protein. That is, a recognition sequence for a restricted angle-digested proteinase is included in advance between the target protein and the conjugate of the ninth subunit, and the target protein is cut out by allowing the protease to act.
- thrombin, FXa (active blood factor X), enterokinase, precision protease, and the like are used as limited-degradation proteases.
- the target protein itself may be protected by the protease, depending on the 'I.
- the target protein is a hepatitis c virus antigen
- its hydrophobicity is so high that the strictness of the recognition sequence of the limited-degraded protease is lost, and the portion other than the recognition sequence is cleaved, resulting in the hepatitis c virus antigen itself. ⁇ will be done.
- Other high hydrophobicity A similar problem exists with proteins that have a region, a region, a transmembrane region, and the like.
- the cleavage efficiency of protease varies depending on the type of target protein. Therefore, in this method, the protease may not be effective depending on the type of the target protein, and the target protein may not be cut out in some cases.
- An object of the present invention is to provide a fusion protein of an intervening protein having molecular chaperone and peptide bond cleavage activity with an objective protein and a gene thereof, a method for producing an objective protein which cleaves the objective protein from the fusion protein by the action of the intervening protein, and a peptide. It is an object of the present invention to provide an intin partial sequence protein having a bond cleavage activity, a gene thereof, an expression vector, and a transformant.
- the present inventors have conducted intensive studies and found that by combining a protein having peptide bond cleavage activity represented by intin with a molecular chaperone, even a protein that is difficult to be expressed by ordinary genetic recombination techniques It has been found that the protein can be efficiently produced as a normal protein. Furthermore, a fusion protein of a target protein and a molecular chaperone and an intervening protein having peptide bond cleavage activity, which is useful in the present production method, was isolated. Further, a partial sequence protein of intin having peptide bond cleavage activity was isolated. Furthermore, the genes encoding them were isolated, and an expression vector containing the gene and a transformant containing the expression vector were isolated, thereby completing the present invention.
- the gist of the present invention is as follows.
- a molecular protein or its subunit is linked to one end of an intervening protein having peptide bond cleavage activity by a peptide bond, and a target protein is attached to the other end.
- a fusion protein characterized by being linked by a peptide bond.
- the intervening protein having peptide bond cleavage activity is linked to a single speronin subunit or a spermnin ninsubunit conjugation; 2.
- the intervening protein having peptide bond cleavage activity is the N-terminus of a single Siaguchi ninsubunit or a conjugate of a Siaguchi ninsubunit, or the N-terminal of a single Siaguchi-subunit or a conjugate of a Siaguchi ninsubunit.
- fusion protein according to any one of (1) to (7), wherein the molecular chaperone is derived from Pacteria, archaea, or eukaryote.
- the intin is derived from Syn ec ho cystiss p.
- the fusion protein according to any one of (9) to (12), which is characterized in that:
- a protein having the amino acid sequence shown in SEQ ID NO: 1 or a protein in which one or several amino acids have been deleted, substituted, added or inserted in SEQ ID NO: 1 The fusion protein according to (12), which is a protein having a sequence and having a peptide cleavage activity.
- the partial sequence protein of intin is a protein having at least 50% homology with the amino acid sequence shown in SEQ ID NO: 1 and having a peptide cleavage activity (12) ).
- a method for producing a target protein characterized in that the target protein is excised from the fusion protein according to any one of (1) to (17) by the action of an intervening protein having peptide-cleaving activity.
- (24) a step of preparing an expression vector incorporating the gene encoding the fusion protein, a step of introducing the expression vector obtained in the previous step into a host to express the fusion protein, and a step of expressing the fusion protein.
- (19) The method for producing a target protein according to (19), further comprising a step of cutting out the target protein from the fusion protein.
- the method for producing a target protein according to (19).
- the fusion protein is expressed in a host, wherein the host is a bacterium, a yeast, an animal cell, a plant cell, an insect cell, an animal individual, a plant individual or an insect individual. (19) to (26) The method for producing a target protein according to any one of the above.
- the molecular protein is a chaperonin, and 5 to 10 cell mouth ninth stubs are assembled in a ring to form a protein mouth ring, and the target protein is (19) to (29), which are housed inside the sash opening nin ring 3.
- the method for producing a target protein according to 1.
- (31) An intin partial sequence protein comprising 20 to 120 amino acid residues from the C-terminus of intin.
- the partial sequence protein of intin is a protein having at least 50% homology with the amino acid sequence shown in SEQ ID NO: 1 and having a peptide cleavage activity (31) ) A partial sequence protein of the intin according to (1).
- Step 1 of preparing a ligated first fusion protein, wherein a molecular chaperone or a submit thereof is ligated to one end of the remaining partial sequence protein of the intin with a peptide bond, and to the other end.
- step 1 Is obtained in step 1 by the step 2 of preparing a second fusion protein in which the second precursor of the target protein is linked by a peptide bond, and the function of cleaving the partial sequence protein of the intin and the remaining partial sequence protein of the intin.
- step 3 of cutting out the first precursor of the target protein from the first fusion protein thus obtained, and further cutting out a second precursor of the target protein from the second fusion protein obtained in the step 2;
- a step 4 of assembling a second precursor of the target protein is
- a partial sequence protein of intin is linked to one end of the molecular chaperone, and the remaining partial sequence protein of the intin is linked to the other end via a peptide bond;
- the target protein first precursor and the target protein second precursor are cut out by the function of cleaving the protein and the remaining partial sequence protein of the intin, and the partial sequence protein of the intin and the remaining partial sequence protein of the intin are cut out.
- a method for producing a target protein comprising assembling a first precursor of a target protein and a second precursor of a target protein by an assembly function.
- the target protein even if the target protein is difficult to be expressed by ordinary gene recombination techniques, it can be expressed as a part of the fusion protein. Furthermore, the target protein is easily and safely cut out by the action of an intervening protein having peptide bond cleavage activity contained in the fusion protein.
- the molecular weight of the fusion protein of the molecular chaperone and the target protein can be reduced. Therefore, the fusion protein can be more easily expressed by gene recombination technology. be able to.
- the partial sequence protein of intin can be expressed by a genetic recombination technique.
- a gene encoding a fusion protein of a target protein and an intervening protein having a molecular chaperone and peptide bond cleavage activity can be prepared only by introducing a gene of the target protein,
- the gene of the fusion protein can be easily introduced into a host.
- the gene for the partial sequence protein of intin can be easily introduced into the host.
- a fusion protein of a target protein and an intervening protein having a molecular chaperone and peptide 'bond cleavage activity can be produced.
- a partial protein of intin can be produced.
- FIG. 1 is a block diagram showing a main part of an expression vector pETDH (TCP] 3) 4 I .
- (TCPj3) 4 is a gene coding for a conjugate of the i3 subunit 4 of Spermonin
- S sp I is a gene coding for intin
- 6 His is a gene coding for 6 histidine residues
- the end is Shows the stop codon.
- FIG. 2 is a photograph showing the results of western blotting analysis of the supernatant of the disrupted cells obtained in Example 1 and Comparative Example 1 using an antibody that recognizes an antibody light chain.
- FIG. 3 (a) is a photograph showing the result of Western blot analysis of the supernatant of the disrupted cells obtained in Example 2 using an antibody that recognizes the hepatitis C virus core antigen.
- FIG. 3 (b) is a photograph showing the results of Western blot analysis of the supernatant of the disrupted cells obtained in Comparative Example 2 using an antibody that recognizes the hepatitis C virus core antigen.
- FIG 4 is a block diagram showing a main part of an expression vector pT (Gr oEL) 7 I.
- (GroEL) 7 is a gene encoding a Gro EL subunit 7 linkage
- NS sp I is a gene encoding an intin sequence modified so that only the N-terminus can be cleaved
- FLA G is FLA The gene encoding the G peptide, and the end indicates the stop codon.
- FIG. 5 shows the results of Western blotting analysis using the anti-FLA G peptide antibody for the cell disrupted supernatants obtained in Example 3 and Comparative Example 3 (1: the bacterial cells of Comparative Example 3).
- Fig. 2 is a photograph showing a disrupted supernatant (2: supernatant of disrupted cells of Example 3).
- FIG. 6 is a block diagram showing a main part of the expression vector pET TPP Iase I.
- TPP Iase represents a gene encoding a TPP Iase sequence
- Ssp I represents a gene encoding intin
- 6His represents a gene encoding 6 histidine residues
- the end represents a termination codon.
- Fig. 7 shows the results of ⁇ ⁇ ⁇ -estane blotting analysis using the histidine-recognizing antibody on the bacterial cell supernatant obtained in Example 4 and Comparative Example 4. ⁇ , 2: Photograph showing the supernatant of the disrupted cells of Comparative Example 4, and 3: GFP-6His standard product.
- Fig. 8 shows the results of Western blotting analysis in Example 5 and Comparative Example 5 (1: control without SspI gene, control by solid butter, 2: supernatant of cell lysate from Example 5). 3: Photograph showing the cell supernatant of Comparative Example 5).
- FIG. 9 shows the results of SDS-PAGEZCBB analysis in Example 5 and Comparative Example 5 (1: the supernatant of the disrupted cell of Comparative Example 5, the fraction of the FLAG column purified from the supernatant of the disrupted cell of Comparative Example 5, 3 is a photograph showing a control using a vector not containing the SspI gene and 4: a FLAG column purified fraction of the control using a vector not containing the SspI gene.
- FIG. 10 is a photograph showing the results of estan blotting analysis in Example 6 and Comparative Example 6 (1: the supernatant of the disrupted cells of Comparative Example 6, 2: the supernatant of the disrupted cells of Example 6).
- Example 7 Western blotting analysis results in Example 7 and Comparative Example 7 (1: GFP-6His standard, 2: Cell disruption supernatant of Example 7; 3: Cell disruption supernatant of Comparative Example 7) It is a photograph showing Qing.
- FIG. 12 is a configuration diagram showing a main part of the expression vector pETDH (TCP / 3) 4 I-2.
- (TCP) 4 is a gene encoding a 4-chaperone subunit linked product
- SspI is a gene encoding intin
- 6His is a gene encoding 6 histidine residues
- the end is a stop codon.
- FIG. 13 is a configuration diagram showing a main part of the expression vector pETDH (TCP 3) 4 MMI-2.
- (TCP) 3) 4 is a gene encoding a 4-linked chaperone subunit
- MMI is a gene encoding MMI
- 6His is a gene encoding 6 histidine residues
- the end is a stop codon.
- Fig. 14 shows the results of Western blotting analysis of the supernatant of the cell lysate obtained in Example 8 and Comparative Example 8 (1: the pETDH (TCP i3) 4 MM I 'AbL_2-introduced cell lysate of Example 8).
- Fig. 15 (a) is a photograph showing the results of analysis of SDS-PAGE and CBB staining of the cell lithotripsy supernatant obtained in Example 9 (1: the cell lysate supernatant of Example 9). It is.
- Fig. 15 (b) shows the results of analysis of the cell lithotripsy supernatant obtained in Comparative Example 9 by SDS-PAGE and CBB staining (2: the bacterial cell crushed supernatant of Comparative Example 9; 3: host cell disruption supernatant).
- FIG. 16 is a photograph showing a result of Western blotting analysis of Example 9 (1: a supernatant of cell disruption of Example 9, 2: a supernatant of host disruption).
- FIG. 17 is a configuration diagram showing a main part of the expression vector pGEX MMI.
- GST indicates a gene encoding daltathione-S-transferase
- MMI indicates a gene encoding MMI
- 6His indicates a gene encoding six histidine residues
- the end indicates a termination codon. .
- FIG. 18 shows the results of western blotting analysis of the supernatant of the cell lysate obtained in Example 10 and Comparative Example 10 (1: the cell supernatant of Example 10-1; 2: the example 10-2).
- 7 is a photograph showing a cell crushed supernatant (3: cell crushed supernatant of Comparative Example 10).
- FIG. 19 is a block diagram showing a main part of the expression vector pET TPP ISE MMI.
- TPP ISE represents a gene encoding TPP ISE
- MMI represents a gene encoding MMI
- 6His represents a gene encoding six histidine residues
- the termination codon is a codon for the coding of a gene encoding six histidine residues.
- FIG. 20 shows the results of Western blotting analysis in Example 11 and Comparative Example 11 (1: GFP-6His standard, 2: Cell disrupted supernatant of Comparative Example 11-1, 3: Cell bacterium of Example 11).
- 4 is a photograph showing a cell homogenate supernatant, 4: the cell homogenate supernatant of Comparative Example 1-2.
- the fusion protein of the present invention comprises an intervening protein having peptide bond cleavage activity, a molecular protein, and a target protein.
- the target protein can be obtained by cutting out the target protein from the fusion protein by the action of an intervening protein having peptide bond cleavage activity.
- Intermediate proteins that have peptide bond-cleaving activity include those that act on other proteins, such as proteases, to cleave peptide bonds in the protein, and those that are themselves, such as intin. Both those that act and autocatalytically cleave peptide bonds are included.
- Examples of the intervening protein having peptide bond cleavage activity contained in the fusion protein of the present invention include protease, intin, hedgehog protein, and self-splicing protein.
- Intin is a protein splicing protein found in eukaryotes, archaea, and eubacteria.
- the intervening protein having the peptide bond-cleaving activity constituting the fusion protein of the present invention is intin
- the fusion protein is cleaved by the autocatalytic action of intin, and the target protein is cut out.
- Natural intin has the activity of cleaving its own N-terminal and C-terminal peptide bonds, and has the activity of connecting the cleaved ends with peptide bonds.
- the intein for constructing the fusion protein of the present invention is preferably a modified intin having only peptide bond cleavage activity and lacking the activity of connecting the both ends of the cleavage by peptide bonds.
- the modified intin can be obtained by substituting a part of the amino acid residue of the natural intin. For example, by modifying the N-terminal cysteine of natural intin to alanine, a modified intin having no C-terminal cleavage activity but only C-terminal cleavage activity (hereinafter, referred to as "C-intin”) Can be obtained.
- C-intin a modified intin having no C-terminal cleavage activity but only C-terminal cleavage activity
- ⁇ -rhintin a modified intin having no N-terminal cleavage activity without C-terminal cleavage activity (hereinafter referred to as ⁇ -rhintin) Can be obtained.
- ⁇ -rhintin N-terminal cleavage activity without C-terminal cleavage activity
- Examples of the origin of intin for constructing the fusion protein of the present invention include, for example, Syn echocystissp. 0 [in the case of 'Cyanocteria Synocystitis p. Examples include My cobacteri um xenopi G yrase A inine), S acchar omy cescerevisiae (S acchar omy cescerevisiaevacuolar membrane ATP intin) and the like.
- Syn echocystiss p. PCC6803 strain DnaBhe1 icase The cleavage activity is maintained even if the central domain having the protease activity is deleted and modified to include only the N-terminal domain and the C-terminal domain.
- any intin other than those listed here can be employed as an intervening protein having peptide-cleaving activity that constitutes the fusion protein of the present invention, as long as it has peptide-bond-cleaving activity. Confuse.
- C intin (hereinafter, referred to as “SspI”) in which the N-terminal amino acid is replaced with alanine except for the endonuclease region of Synechnocystissp.
- PC strain 680 strain DnaBhe1 icase intin The amino acid sequence corresponding to the base sequence of the encoded gene is shown in SEQ ID NO: 3, and only the corresponding amino acid sequence is shown in SEQ ID NO: 4.
- the intervening protein having peptide bond cleavage activity may not be full-length intin but may be a partial sequence protein of intin and may have the same activity as full-length intin.
- the partial sequence protein of intin in the fusion protein of the present invention is selected from the group of proteins consisting of 20 to 120 amino acid residues from the C-terminus of intin. These partial proteins of the intin have the same protein splicing function as the full-length intin, and have the activity of cleaving the C-terminal peptide bond of itself.
- the protein consisting of 20 to 120 amino acid residues from the C-terminus of the amino acid sequence of Ssp I represented by SEQ ID NO: 4 has the same functions as the full-length S sp I, Applies to the fusion protein of the present invention. More preferably, a protein consisting of 48 amino acid residues from the C-terminus of the amino acid sequence of SspI represented by SEQ ID NO: 4 (hereinafter referred to as “MMI”), the fusion protein of the present invention It is suitable as a component of.
- the amino acid sequence of MMI is shown in SEQ ID NO: 32.
- a protein having an amino acid sequence in which one or several amino acids of the amino acid sequence represented by SEQ ID NO: 32 has been deleted, substituted, added or inserted, and having peptide cleavage activity is also suitable as a component of the fusion protein of the present invention.
- a protein having at least 60% or more homology with the amino acid sequence represented by SEQ ID NO: 32 preferably a protein with 80% or more homology, more preferably a 90% or more homology.
- the partial sequence protein of intin other than the above examples has peptide bond cleavage activity, it can be a component of the fusion protein of the present invention.
- examples of the gene encoding MMI include an isolated DNA having the base sequence shown in SEQ ID NO: 31.
- a DNA that can hybridize to the DNA shown in SEQ ID NO: 31 under stringent conditions and encodes a protein having a peptide cleavage activity encodes a protein substantially identical to MMI.
- the hybridizable DNA means a DNA detected by using a certain DNA as a probe and using a colony hybridization method, a plaque hybridization method or a Southern blot hybridization method, or the like. I do.
- the stringent conditions are as follows: 0.1 XSSC solution (1X concentration of SSC solution is 150 mM sodium chloride, 15 mM sodium citrate), 1% SDS, 65 ° C, 24 hours Say. DNA that hybridizes under these conditions is DNA substantially identical to the MMI gene shown in SEQ ID NO: 31. Hybridization is based on Molecular 'Cloning 2nd Edition, Current Procalls' in Molecular Biology, DNACloning 1: Core Technich, AP ractica 1 Ap proach, This can be performed according to the method described in S econd Edition, O ford University (1995) and the like.
- the intervening protein having a peptide bond cleavage activity is other than intin, for example, in the case of a protease, an amino acid sequence recognized by the protease is inserted between the protease and the target protein, whereby the action of the protease
- the fusion protein can be cleaved.
- the hedgehog protein is an extracellular secretory signal transmitter of Drosophila and has the activity of cleaving peptide bonds for its own processing.
- This hedgehog protein is also a fusion protein of the present invention. Can make up proteins.
- the protease ⁇ hedgehog protein also Not only those but also partial proteins having the same activity can constitute the fusion protein of the present invention.
- the term “protease ⁇ hedgehog protein” also includes a protein having a partial sequence protein having an activity similar to that of a full-length natural protein.
- the target protein constituting the fusion protein of the present invention is not particularly limited, and is a disease-related gene product derived from a higher animal such as a human or a mouse, or any of a group of enzymes effective for a chemical process, or the disease-related gene product.
- useful proteins such as enzymes. Specifically, coat proteins, core proteins, proteases, reverse transcriptases, integrases encoded by pathogenic viral genomes such as hepatitis B virus, hepatitis C virus, HIV, influenza virus, and coronavirus And other proteins (viral antigens).
- proteins serving as antibodies against these pathogenic viruses heavy chains of mammalian antibodies, light chains of mammalian antibodies, constant regions of mammalian antibodies, Fv region single-chain antibodies of mammalian antibodies (sc FV ) Or a partial protein thereof having 6 or more residues, Fab (antigen-binding fragment), (Fab ') 2 fragment, CH1-CH2-CH3 fragment, CH1-CH2 fragment, CH2-CH3 fragment, CH1 fragment, CH2 fragment, CH3 fragment, 'CL fragment, and therapeutic / diagnostic antibody which is a complete antibody type.
- G protein-coupled receptors G protein-coupled receptors
- platelet growth factor blood stem cell growth factor
- hepatocyte growth factor transforming growth factor
- nerve growth and nutrition factor fibroblast growth factor
- Growth factors such as insulin-like growth factor; tumor necrosis factor, interferon, erythropoietin, condyle granulocyte colony stimulating factor, macrophage colony stimulating factor, granulocyte macrophage colony stimulating factor, interleukin 3 and interleukin 5 Cytolein such as interleukin, ⁇ / levumin, human growth hormone, and the like.
- a green fluorescent protein (hereinafter, referred to as "GFP") which can be used as a fluorescent label of a functional protein in a cell to observe a phenomenon in a living cell can be mentioned.
- GFP green fluorescent protein
- an artificial protein obtained by linking two or more proteins selected from these proteins can also be applied as the target protein constituting the fusion protein of the present invention.
- the molecular chaperone or its subunit constituting the fusion protein of the present invention is not particularly limited, as long as it has an action of assisting protein folding. You. Examples thereof include shanin, which is a complex of a plurality of shanin subunits, and beptidyl prolyl cis trans isomerase (hereinafter, referred to as PPIase).
- shanin which is a complex of a plurality of shanin subunits
- PPIase beptidyl prolyl cis trans isomerase
- the molecular chaperone includes a molecular chaperone that acts as a single molecule and a molecular chaperone that forms a complex composed of a plurality of subunits.
- the fusion protein of the present invention includes the former molecular chaperone, the molecular protein of the single molecule is linked to the intervening protein.
- the latter contains a molecular chaperone, the subunit is linked to the intervening protein.
- An example of the former is PP ISE, and an example of the latter is Shakonin.
- Sharpen is a complex of about 1 to about 20 subunits of about 60 kDa (chadronin subunits). Sharp nin is also known as a type of heat shock protein induced by applying stress such as heat shock to cells. Chaperone port Nin, bacteria (e.g., E. coli, etc.), Archaea (e.g., Th e rmo coccuss p. N Py rococcusorikoshil ⁇ Ae ropyrumpernix etc.) and eukaryotic (e.g., yeast, mouse, human, etc.) All such It has functions of supporting protein folding and preventing degeneration.
- bacteria e.g., E. coli, etc.
- Archaea e.g., Th e rmo coccuss p. N Py rococcusorikoshil ⁇ Ae ropyrumpernix etc.
- eukaryotic e.g., yeast, mouse, human, etc. All such It has
- An artificial protein in which a plurality of sugar mouth subunits are connected in series via peptide bonds also forms a complex in the same manner as natural sugar mouth subunits. It is known to form. At this time, it is known that from 2 to about 10 sap mouth ninth subunits have a linear or ring-like structure (hereinafter, also referred to as sham mouth nin ring) as in the case of natural sap mouth nin. ing.
- a chaperonin supplement that is not linked via a peptide bond to another sharonin subunit is referred to as a “single sharonin subunit”. Unit.
- the target protein is the N-terminal of a single Shah Nin Subunit or a Shah Nin Subunit conjugate, the C terminal of a single Shah Nin Subunit or a Sharonin Subunit conjugate, a Shah mouth It is linked to one or more sites selected from the linking portion of the ninsubunit linked bodies between the chaperonin subunits via an intervening protein having peptide bond cleavage activity.
- the target protein is a cavity composed of a plurality of spore ninth subunits, ie, one layer or It is preferable to select a binding site of the target protein so that it is stored inside two or more layers of the scallop nin ring.
- Shaguchinin which is an example of a molecular chaperone that constitutes the fusion protein of the present invention, has a two-layered ring structure composed of 10 to 20 sugar mouth subunits, that is, 5 to 10 sharonins. What forms a two-layer structure in which the sub-unit shunt mouth rings are non-covalently associated via the ring surface (hereinafter, the two-layer ring structure is also referred to as a chaperonin complex) It is suitable.
- Escherichia coli Shaguchinin GroEL having a cavity (cavity) having an inner diameter of 4.5 nm and a height of 14.5 nm is suitable.
- the fusion protein When using Shakonin as a molecular chaperone, it is preferable to configure the fusion protein such that the target protein is housed inside the Shakonin ring.
- chaperonin derived from bacteria or archaebacteria can be easily expressed in a host, and is therefore particularly suitable for producing the fusion protein of the present invention.
- not only wild-type but also amino acid mutants can be used as the above-mentioned porphyrin as long as the ability to self-assemble into a ring structure is maintained.
- the stored target protein can be more easily recovered.
- expression of Shanin nin subunit derived from the same bacteria as the host often increases the expression level. As a result, the production efficiency of the target protein is often improved.
- the number of Shakonin nin subunits constituting Shakonin varies depending on the organism from which it is derived.
- the number of subunits is usually seven in bacterial mouthnin from bacteria.
- the number is usually 8 to 9 for archaea-derived Shakonin, and usually 8 for eukaryotic Shanin. Therefore, the optimal number of scharinnin submits of the chaperonin constituting the fusion protein of the present invention can be selected depending on its origin.
- the ratio of the number of Shaunjun unit for forming a ring structure to the target protein is usually 1: 1 to 10: 1, and preferably 1: 1 :! to 9: 1.
- the ratio of the number of spore mouth ninsubunits is larger than 10: 1, the actual production amount of the target protein to be expressed decreases, and it becomes difficult to form the ring structure of the spore mouth ninsubunit.
- the sperm nin subunit the target protein is used because of the low structural formation of the speromin complex.
- the ratio of the numbers is preferably 1: 1 or 7: 1.
- the scherichia coli nin subunit is composed of: The ratio of the numbers is preferably 1: 1, 2: 1, 4: 1 or 8: 1.
- PPIase is one of the protein folding factors involved in protein folding. Among amino acids in the target protein that is undergoing intracellular folding, PPIase binds to the N-terminal peptide bond of the proline residue. It has the activity of catalyzing the trans isomerization reaction (PPase activity).
- PPlase is classified into three types, FK506BindngProtein type (FKBP type), cyclophilin type, and perpurin type, based on its sensitivity to the inhibitor.
- FKBP type FK506BindngProtein type
- Cyclophilin-type PPlase is PPlase or a homologue thereof that is sensitive to another immunosuppressant, cyclosporin.
- parbulin-type PPlase does not show sensitivity to any immunoinhibitors, and its activity is inhibited by juglone (jug1one).
- juglone jug1one
- the PPIase constituting the fusion protein of the present invention is not particularly limited, and any of the above three types of PPIases may be used.
- the FKBP-type PPIase include archaebacterial-derived FKBP-type PPIase, trigger factor one type PPIase (Hu ang, Protein Sci., Vol. 9, p. 1254, 2000), F kp A type PPI ase (Arie, MoI. Microbiol., Vol. 39, p. 199, 2001), FKBP 52 type PPI ase (Bose, Science, Vol. 274, p. 1715, 1996).
- cyclophilin-type PPIase include CyP40-type PPIase (Pirkl, J.
- examples of the purpurin-type PPIase include SurA-type PPIase (Behrens, EMBO J., p. 20, p. 285, 2001).
- these PPases have very similar amino acid sequences.
- Molecular chaperone activity is an activity that was originally found in a protein chaperone known as one of the molecular chaperones and the DnaDnaJ / GrpE protein folding system. These serve to support the polypeptide synthesized in the cell so that it is folded into the correct shape. At that time, it requires the addition of high-energy substances such as ATP; On the other hand, the archaeon-derived FKBP-type PPlase differs in that it does not require the above-mentioned high-energy substance hydrolysis reaction when exerting its molecular chaperone activity. Archaeal origin! ⁇ type? Iase is particularly suitable as a PPIase that constitutes the fusion protein of the present invention because it can fold the target protein more correctly than PPIase without molecular chaperone activity.
- any PP Iase having the molecular chaperone activity in the present invention can be suitably used.
- the method for producing a target protein of the present invention is a method for cleaving a fusion protein by the action of an intervening protein having a peptide bond-cleaving activity, such as intin, and excising the target protein from the S-mating protein. More specifically, a step of isolating the fusion protein, a step of inducing a peptide bond cleavage activity of an intervening protein having peptide bond cleavage activity contained in the isolated fusion protein, and a step of having peptide bond cleavage activity Cleaving a part of the fusion protein by the action of the intervening protein, cutting out the target protein from the fusion protein and releasing it.
- an intervening protein having a peptide bond-cleaving activity such as intin
- a target protein that is insoluble or the like by itself is subjected to molecular shaping.
- the protein can be expressed as a normal protein by the action of the protein, and the target protein can be cut out without adding protease or the like.
- the expression of the fusion protein may be performed in a host or a cell-free translation system. .
- the gene of the fusion protein is introduced into the host.
- a gene encoding the fusion protein is introduced into an appropriate vector to construct an expression vector, and then introduced into an appropriate host to obtain a transformant.
- the transformant is cultured to express the fusion protein, and the fusion protein is isolated from the transformant.
- the fusion protein is expressed in a cell-free translation system, fusion is performed in a reaction mixture containing a nucleotide-free phosphate or various amino acids in a cell-free extract of, for example, Escherichia coli, wheat germ, or egret reticulocytes. The protein can be expressed.
- the isolated fusion protein is subjected to a treatment for inducing the peptide cleavage activity of the intervening protein, and the target protein is cut out from the fusion protein and released.
- the treatment for inducing the peptide cleavage activity of the intervening protein include pH control, temperature control, and addition of a trigger substance if the intervening protein is intin.
- the peptide bond cleavage activity of intin can be induced by changing the hydrogen ion concentration so that the pH is in the range of 6 to 8, preferably around 7. Further, by changing the temperature so as to be in the range of 20 to 37 ° C., the peptide bond cleavage activity of intin can be induced.
- thiol such as dithiothreitol or j8-mercaptoethanol
- the peptide bond cleavage activity of intin can be induced.
- thiols are effective in inducing N-intin cleavage activity.
- preventing the peptide bond cleavage activity of intin from being induced before isolating the fusion protein, that is, in the host or in a test tube is also effective in increasing the yield of the target protein.
- the method include setting the culture temperature of the host at less than 20 ° C and performing cell-free protein synthesis at less than 20 ° C.
- peptide bond cleavage activity can be induced by controlling the optimal buffer conditions, temperature, pH, etc., depending on the type of protease. ,
- the host for expressing the gene encoding the fusion protein in the host is not particularly limited, and includes, for example, bacterium such as Escherichia coli, other prokaryotic cells, yeast, insect cells, cultured mammalian cells, cultured plant cells, and the like. ⁇ Transgenic animals and plants.
- Pacteria such as Escherichia coli and yeast are particularly preferable because they have a high cell proliferation characteristic, the culturing operation is simple, and the cost of nutrient sources used for culturing is low.
- the fusion protein may be expressed either in the host cytoplasm or extracellularly, but if it is to be expressed in large amounts, it is more preferable to express it in the cell.
- the expression level can be prevented from decreasing by means for co-expressing the fusion protein in the same host.
- the same gene that synthesizes the same fusion protein is introduced into vectors such as two types of plasmids having different replication regions and drug resistance genes, and these two types are used in the presence of two types of drugs.
- two different plasmids capable of coexisting and replicating a gene encoding a fusion protein and a gene encoding only a molecular chaperone in the same host are used. And may be co-expressed in the same host. For example, when the number ratio of the Shanin nin subunit to the target protein is small, the gene encoding the fusion protein and the gene encoding only the Shanin nin subunit can coexist and replicate in the same host. It is advisable to introduce two types of plasmids to co-express the fusion protein and the ninja ninsubunit.
- the partial sequence protein of intin and the remaining protein obtained by removing the partial sequence protein from the full-length intin are so-called trans-splicing (WuH).
- WH trans-splicing
- the partial protein of intin and the residual protein of intin have a function of assembling two types of proteins (assembly function). Using this assembly function, two types of target proteins can be assembled. For example, two types of proteins When it is a precursor of a target protein, the target protein can be produced by assembling / reassembling these precursors.
- the target protein is immunoglobulin and the precursor is an antibody light chain and an antibody heavy chain
- the first example is that the C-terminal partial sequence protein of intin is placed at the c-terminal of the molecular chain.
- a fusion protein in which the antibody heavy chains are linked via the is prepared. Then, the two fusion proteins are brought close to each other to cause assembly, and an immunoglobulin in which an antibody heavy chain and an antibody light chain are linked by a disulfide bond can be produced.
- the antibody heavy chain is linked to the C-terminus of the molecular chaperone via the C-terminal partial sequence protein of intin
- the residual protein of intin is linked to the N-terminal of the molecular chaperone.
- the antibody heavy chain and the antibody light chain are assembled using one function of intin assembly, and an immunoglobulin in which the antibody heavy chain and the antibody light chain are linked by a disulfide bond can be produced.
- the residual protein of the intin may contain an end nuclease active portion. Examples-Hereinafter, the present invention will be described specifically with reference to examples, but the present invention is not limited to these examples.
- SEQ ID NO: 3 shows the amino acid sequence corresponding to the nucleotide sequence
- SEQ ID NO: 4 shows only the amino acid sequence.
- S spl is a modified intin in which the N-terminal amino acid is substituted with alanine except for the endonuclease region of the DnaBhel1 icase intin derived from the Cyanobacteria Synechocystissp PCC 6803 strain.
- Genome D from Th e rmo c o c c u s KS— 1 strain JCM No. 11816
- TCP3 4 a gene of a TCP] 34 ligated product
- oligonucleotides having complementary nucleotide sequences represented by SEQ ID NOs: 36 and 37 were synthesized, and annealed to obtain double-stranded DNA having a multiple cloning site.
- This double-stranded DNA encodes a histidine tag (6His, SEQ ID NO: 8) consisting of 6 residues of histidine downstream of the NcoI, BamHI, Spel, and Hpal sites. Gene, a stop codon and a NotI site.
- this double-stranded DNA was introduced into the NcoI-NotI site of the pET21d plasmid (Novagen).
- the (TCP) 4 gene isolated in this example was introduced into the BamHI site of this plasmid to construct pETDH (TCP j3) 4 . Furthermore, the SspI gene isolated in this example was inserted downstream of the (TCPi3) 4 gene of pETDH (TCP j3) 4 to construct the expression vector pETDH (TCPi3) 4 I.
- FIG. 1 shows the structure of a p ETDH (TCP j3) 4 I . That is, pE TDH (TCP j3) 4 I has a T7 promoter, and the (TCPi3) 4 gene, the Sspl gene, and the 6HIs gene are arranged downstream thereof. Further, by a child inserts a stop codon to a gene encoding a desired protein between the p ETDH (TCP] 3) 4 I S pe I Sa I doo and Hp a I sites, having 6H IS to C-terminus, A vector that expresses a fusion protein of (TCP / 3) 4 , SspI, and a target protein can be constructed.
- the DNA fragment containing the light chain (AbL) gene of the human anti-HBs (hepatitis B virus surface protein) antibody shown in SEQ ID NO: 9 was prepared by synthesizing long chain DNA.
- the DNA fragment had a Spe I site at the 5 'end and a Hpa An I site has been set up.
- This DNA fragment was treated with S pe I and H pa I, were incorporated into expression previously treated with the same restriction enzymes downy compactors p ETDH (TCP ⁇ ) 4 I .
- an expression vector p ETDH (TCP i3) 4 I ′ Ab L for synthesizing a fusion protein of (TCP; 3) 4 , S sp I and Ab L was constructed.
- the resulting expression vector p ETDH the (TCP i3) 4 I '1 ) tooth was introduced into E. coli 81 ⁇ 2 1 (DE 3) strain (S tratagene Co.), to obtain a transformant.
- the cells were suspended in 5 OmM Tris HC1 buffer 0.2 mM EDTA ( ⁇ 70 ⁇ 0), and the cells were disrupted by ultrasonic treatment in the presence of protease inhibitors (Nakarai Testa). Thereafter, the supernatant of the cell lysate was obtained by centrifugation.
- FIG. 3 (a) (Example 2) and FIG. 3 (b) (Comparative Example 2).
- lane 1 is the sample of Example 2
- lane 2 is a control using only the host.
- Lane 3 in FIG. 3B is the sample of Comparative Example 2.
- HCc was detected at a molecular weight of about 21 kDa, and HCc was cut out from the fusion protein without degradation. confirmed.
- Fig. 3 (b) in the cell lysate of Comparative Example 2, signals were detected around 18 kDa, 15 kDa and around 12 kDa in addition to the signal around 21 kDa in molecular weight. c turned out to be: ⁇ ⁇ . This is because HCc has particularly high hydrophobicity, and the strictness of the recognition sequence by the limited-degrading protease is lost. It is probable that a break occurred inside C.
- PCR was carried out using pTWINl (New England Bio 1 abs) as type I, oligonucleotides shown in SEQ ID NOS: 12 and 13 as primers, and modified so that only the N-terminal shown in SEQ ID NO: 6 could be cleaved.
- a DNA fragment containing a gene encoding spI (hereinafter, referred to as “NS spI”) was isolated.
- NS sp I is a modified intin (N intin) in which the C-terminal amino acid is substituted with alanine except for the endonuclease region of the Dna Bhe1 icasse intin derived from the cyanobacterium Synecstispssp PCC 6803 strain.
- Genomic DNA was extracted from E. coli HMS 174 (DE3) strain (Novagen). Using this genomic DNA as type III, PCR was carried out using the oligonucleotides shown in SEQ ID NOS: 15 and 16 as primers, and a DNA fragment containing the Gro EL subunit gene shown in SEQ ID NO: 17 was isolated. On the other hand, oligonucleotides having base sequences complementary to each other as shown in SEQ ID NOs: 38 and 39 were synthesized, and annealed to obtain double-stranded DNA having a multicloning site.
- NcoI, XbaI, Bg1II, and XhoI sites are arranged in order, and a gene encoding the FLAG peptide (SEQ ID NO: 18) and the downstream are located downstream. Has codons.
- this double-stranded DNA was introduced into the NcoI-HindIII site of plasmid pTrc99A (Amersham Bioscience). Furthermore, the DNA fragment containing the Glo EL subunit gene amplified above was introduced into the introduced XbaI site.
- the gene of a 7-fold Glo EL subunit in which seven Glo EL subunit genes are linked in tandem (hereinafter, referred to as “(GroEL) 7 ”) is inserted.
- PT (GroEL) 7 was constructed.
- Figure 4 shows the pT (Gr o EL) of 7 NI structure.
- pT (GroEL) 7 NI has a trc promoter, and 7 Gr o
- the gene of the Gro EL subunit 7-fold ((Gro EL) 7 ) gene in which the EL subunit genes are arranged in tandem, the NS sp I gene, and the gene encoding the FLAG peptide are arranged in this order.
- a fusion protein of (GroEL) 7 , NSspI and the target protein should be expressed by inserting a gene encoding the target protein between the Bg1II site and the XhoI site. Can be built.
- a DNA fragment containing the acetylcholine musculin force receptor (MR) gene shown in SEQ ID NO: 19 was isolated by long-chain DNA synthesis. Incorporating the DNA fragment between pT (Gr oEL) 7 NI B g 1 II ⁇ Pi Xh o I site. As a result, an expression vector pT (Gro EL) 7 NI ⁇ ⁇ R for synthesizing a fusion protein of (GroEL) 7 , NS sp I, and MR was constructed. Using PT (GroEL) 7 NI'MR, perform the transformation and culture of the transformant in the same manner as in Example 1 except that the culture temperature is 25 ° C. Obtained.
- the supernatant of the bacterial cell clot was purified with a column carrying an anti-FLAG peptide antibody, and dithiothreitol (DTT) at a final concentration of 4 OmM was added to cleave the N-terminal peptide bond of NSspI.
- DTT dithiothreitol
- Western blotting using an anti-FLAG peptide antibody was performed. The result is shown in lane 2 in Fig. 5.
- Example 3 After 4 hours of purification of the supernatant obtained in Example 3 using the FLAG peptide antibody-carrying capacity column, Western blotting using an anti-FLAG peptide antibody was performed without adding DTT. . The results are shown in lane 1 in FIG. In Example 3, a signal of the fusion protein of NS sp I and MR was detected at a molecular weight of around 52 kDa, confirming that MR was excised from the fusion protein (lane 2). On the other hand, in Comparative Example 3, no signal near the molecular weight of 52 kDa was detected, and it was confirmed that MR was not cut out from the fusion protein (lane 1). Thus, the cleavage activity of intin was triggered by DTT. (Example 4) 1. Construction of a fusion protein expression system with PPI ase
- Genomic DNA was extracted from ThermococcusKS-1 strain (JCM No. 11816). Using this genomic DNA as type III, PCR was performed using the oligonucleotides shown in SEQ ID NOS: 20 and 21 as primers, and contained the PTPase (TPP Iase) gene derived from the hyperthermophilic archaea shown in SEQ ID NO: 22 The DNA fragment was isolated.
- PTPase TPP Iase
- PETDH (TCP) 4 ⁇ I prepared in Example 1 was treated with BamHI and NotI to isolate a DNA fragment containing the SspI gene, the His tag and the stop codon.
- an oligonucleotide represented by SEQ ID NO: 35 and an oligonucleotide having a nucleotide sequence complementary thereto were synthesized and annealed to obtain a double-stranded DNA fragment.
- This double-stranded DNA fragment was introduced into the NcoI site of pET21d plasmid (Novagen).
- the DNA fragment containing the TP PIase gene amplified in this example was inserted into the NcoI_SpEl site contained in the introduced DNA fragment.
- FIG. 6 shows the structure of pETTPPase I. That is, pETPPPIase I has a T7 promoter, and a TPPIase gene, an SspI gene, and a 6His gene are arranged downstream thereof in this order.
- GFP green fluorescent protein
- GFP WT (Roche Diagnostics) was type III, PCR was performed using the primers of SEQ ID NOS: 23 and 24 as a primer, and the green fluorescent protein represented by SEQ ID NO: 25 was obtained.
- a DNA fragment containing the (GFP) gene was isolated. The DNA fragment was provided with a SpeI site at the 5 and terminus and an HpaI site at the 3 and terminus, respectively, from the primer. This DNA fragment was treated with SpeI and HpaI and incorporated into an expression vector PETTPPaseI, which had been treated with the same restriction enzymes in advance. As a result, it is possible to obtain PP Iase (TPP Iase) derived from hyperthermophilic archaea.
- An expression vector pETTPPIaseI ⁇ GFP for synthesizing a fusion protein of SspI and GFP was constructed.
- the resulting expression vector pETTPPIaseIGFP was introduced into E. coli strain BL21 (DE3) to obtain a transformant.
- 25. Transformants in 2X ⁇ . ⁇ medium containing carbenicillin (100 ⁇ g ZmL). C, and cultured for 24 hours to express a fusion protein of TPPIase, Ssppl, and GFP.
- the cells were suspended in 50 mM Tris / HC1 buffer (pH 7.0), disrupted by sonication in the presence of a protease inhibitor cocktail, and then centrifuged. The supernatant was obtained. (Comparative Example 4)
- pET TP PIase I shown in Fig. 1
- pET was introduced between the BamHI site and the SpeI site, instead of the gene encoding SspI, a gene encoding a recognition sequence for precision protease was introduced.
- TPP Iase P was constructed.
- Example 4 In the cell lysate of Example 4 (lane 1), GFP was detected at a molecular weight of around 27 kDa, and it was confirmed that GFP was excised from the fusion protein.
- the signal in the vicinity of 62 kDa in lane 1 is a fusion protein of TPPIase, Sspl, and GFP.
- lane 2 On the other hand, in the cell lysate of Comparative Example 4 (lane 2), a signal was detected only around the molecular weight of 45 kDa of the fusion protein of TPPIase and GFP, and GFP excision was not confirmed.
- Lane 3 is a sample of GFP. (Example 5) 1. Expression and cleavage of endothelin receptor
- pT (GroEL) 7 I was constructed in the same manner as in Example 3 at around jl.
- pT (Gr oEL) 7 I is a vector incorporating the S sp I gene in place of the NS sp I gene pT (Gr oEL) 7 NI shown in FIG.
- the human cDNA library (Takarabay Saisha) was type III, PCR was performed using the oligonucleotides shown in SEQ ID NOs: 26 and 27 as primers, and the endoselin A receptor (ETAR) shown in SEQ ID NO: 28 was obtained. A DNA fragment containing the gene was isolated.
- the supernatant of the cell lysate was purified using a column carrying an anti-FLAG peptide antibody, and the presence or absence of cleavage of the C-terminal peptide bond of SspI was determined by using an anti-FLAG peptide antibody (SI GMA anti-FLAG M 2 monoclonal antibody). The results are shown in lane 2 in FIG.
- the culture was carried out in the same manner as in Example 5 except that the culture temperature of the transformant of Example 5 was changed to 25 ° C. instead of 18 ° C., and a supernatant of the disrupted bacterial cells was obtained.
- the supernatant of the cell lysate was purified by a column carrying an anti-FLAG peptide antibody, and the presence or absence of cleavage of the C-terminal peptide bond of SspI was confirmed by Western blotting using an anti-FLAG peptide antibody.
- the results are shown in lane 3 in FIG.
- an ETAR signal was detected at a molecular weight of around 42 kDa, confirming that ETAR was cut out from the fusion protein (lane 2).
- Lane 1 is a control using a vector that does not contain the SspI ⁇ gene. Further, the fraction obtained by purifying the supernatant of the disrupted cells obtained in Comparative Example 5 using a column carrying an anti-FLAG peptide antibody was subjected to SDS-PAGE and CBB staining to confirm the presence or absence of a band. As a control, SDS-PAGE was also performed on the fraction that had been similarly cultured, disrupted, and purified of the fusion protein of SET-free (Gro EL) 7 and ETAR.
- Figure 9 shows the results.
- lane 1 is the supernatant of the disrupted bacterial cell obtained in Comparative Example 5
- lane 2 is the FLAG column-purified fraction of the supernatant
- lane 3 is the supernatant of the disrupted bacterial cell of the control
- lane 4 is This is the FLAG column purified fraction of the supernatant.
- the fusion protein of Ssp I-free (GroEL) 7 and ETAR a band was detected in the fraction purified by the anti-FLAG peptide antibody-bearing column (lane 4).
- Example 5 a DNA fragment containing the endothelin A receptor (ETAR) gene shown in SEQ ID NO: 28 was isolated.
- EDR endothelin A receptor
- the supernatant of the cell lysate was purified using an anti-FLAG peptide antibody-supporting column, and DTT at a final concentration of 40 mM was added to cleave the N-terminal peptide bond of NSspI.
- the result of stamp lotting using an anti-FLAG peptide antibody is shown in lane 2 of FIG. (Comparative Example 6)
- the supernatant of the cell lysate of Example 6 was purified using a FLAG peptide antibody-supporting column, and the result of Western blotting using an anti-FLAG peptide antibody without adding DTT was used. Shown in the cell homogenate of Example 6, the signal of the fusion protein of NS sp I and ETAR was detected at a molecular weight of around 59 kDa, confirming that ETAR was cut out from the fusion protein (lane 2). On the other hand, in the cell lysate of Comparative Example 6, no signal near the molecular weight of 59 kDa was detected, and it was confirmed that ETAR was not cut out from the fusion protein (lane 1). Thus, the intact cleavage activity was triggered by DTT.
- Protein synthesis was carried out in the same manner as in Example 4 except that cell-free protein expression (using Roche Diagnostics RTS 500) was performed instead of culturing E. coli.
- Protein synthesis was performed in the same manner as in Comparative Example 4 except that cell-free protein expression (using Roche Diagnostics RTS 500) was performed instead of culturing E. coli.
- the reaction solution after protein synthesis prepared in Example 7 and Comparative Example 7 was purified by Ni-NTA agarose gel (Qiagen) and treated at room temperature for 2 hours.
- Western blotting analysis was performed using a Nore antibody (Santa Cruz Biotechnology) to examine whether GFP was cleaved from TPP Iase. The results are shown in FIG. Lane 1 is the control with GFP-6His.
- PCR was performed using p TWI N1 (New England Bio 1 abs) as a type III, oligonucleotides shown in SEQ ID NOs: 29 and 30 as primers, and MM, which is the C-terminal partial sequence of SspI
- SEQ ID NO: 31 shows the amino acid sequence corresponding to the nucleotide sequence
- SEQ ID NO: 32 shows only the amino acid sequence. That is, MMI corresponds to the portion from the C-terminus of S sp I to the 48th amino acid.
- oligonucleotides represented by SEQ ID NOS: 40 and 41 Two types of oligonucleotides represented by SEQ ID NOS: 40 and 41 were synthesized, and annealed to prepare a double-stranded DNA encoding 6His.
- the double-stranded DN A was introduced into N co I site upstream of Example 1 with the prepared expression vector p ETDH (TCP ⁇ ) on 4 I of (TCP) 4 gene, the expression vector p ETDH (TCP ⁇ 4 ) I-2 was constructed. Shows the structure of a p ETDH (TCP j3) 4 I- 2 1 2.
- p ETDH (TCP j8) 4 I _ 2 has a T 7 promoter, downstream thereof, 6H IS gene, (TCP) 4 gene, and S S p I gene are arranged in this order. Further, by inserting a gene encoding a desired protein between the p ETDH (TC P j3) 4 1 _ 2 of S pe I site and Hp a I sites, with the H IS tag at the N-terminus, (TCP ; 8) A vector that expresses a fusion protein of 4 , SspI, and a target protein can be constructed.
- p ETDH instead of (TCP j3) 4 I- 2 of S sp I, was constructed MM I gene introduced expression vector p ETDH (TCP j3) 4 MM I _ 2.
- Figure 13 shows the configuration of p ETDH (TCP j8) 4 MMI-2. That is, the configuration of the p ETDH (TCP j8) 4 MM I- 2 is substantially the same as p ETDH (TCP ⁇ ) 4 I- 2, only in that S sp I gene is replaced by a MM I gene are different.
- the resulting expression vectors p ETDH (TCP ⁇ ) 4 I Ab L_ 2 and p ETDH (T CP j3) 4 MMI 'Ab L-2 were each introduced into E. coli strain BL 21 (DE 3) to form Transformant was obtained. These transformants were cultured in a 2XY.T. medium containing carbenicillin (100 / g / mL) at 30 ° C for 24 hours, and (TCP jS) 4 , SspI and AbL And a fusion protein of (TCP) 4 with MMI and Ab L was expressed.
- Example 8 p ETDH (TCP) 3) 4 MMI ′ Ab L—2 (lane 1) and p ETDH (TCP jS) 4 I
- the molecular weight was detected around 25 kDa, and it was confirmed that AbL was excised from each fusion protein.
- the band around 250 kDa is the fusion protein of (TCP i3) 4 with MMI and Ab L (lane 1) or the fusion protein of (TCP ⁇ ) 4 with S s ⁇ I and Ab L (lane 2).
- Comparative Example 8 In (lane 3) the molecular weight was detected only around 250 kDa, and Ab L was not excised from each fusion protein.
- the signal intensities of lane 1 and lane 2 were compared, they were almost the same. That is, the activity of cleaving the target protein was comparable between MMI and SspI.
- the resulting expression vector p ETDH the (TC P] 3) 4 MM I ⁇ A b H- 2 was introduced into E. coli BL 2 1 (DE 3) strain to obtain a transformant.
- the transformant was cultured in a 2XY.II. medium containing carbenicillin (100 ⁇ g / mL) at 30 ° C for 24 hours, and a fusion protein of (TCP 3) 4 with MMI and AbH Was expressed.
- the cells were collected, suspended in 50 mM Tris / HCl buffer, 0.2 mM EDTA (pH 7.0), and disrupted by sonication in the presence of protease inhibitor. The supernatant of the cell suspension was obtained by centrifugation.
- Comparative Example 9 On the other hand, in lane 2 (Comparative Example 9), a very thin band was formed around 300 kDa, and no force was detected. That is, the expression level of Comparative Example 9 was considerably lower than that of Example 9. As described above, when the target protein is AbH of about 50 kDa, in the fusion protein of (TCP i3) 4 prepared in Comparative Example 9, SspI and AbH, SspI and AbH It was considered that expression did not occur or the expression level decreased drastically because it could not fit into the mouth cavity. On the other hand, when the partial sequence MMI was introduced instead of SspI as in Example 9, the fusion protein could be expressed without any particular problem. This was thought to be due to the fact that MMI and Ab H fit into the Shaw Nin's cavity.
- the supernatant of the cell lysate from the expression vector pETDH (TCP ⁇ ) 4 MMI ⁇ AbH obtained in Example 9 was treated at room temperature for 2 hours to cut out AbH from the fusion protein.
- AbH is excised from the fusion protein by Western blotting analysis using an antibody that recognizes the antibody heavy chain (PI ERCE Goat anti-human IgG F (ab ') 2 antibody _HRP conjugate) I checked my strength.
- the results are shown in FIG. As a result, a signal was detected at a molecular weight of around 50 kDa, confirming that AbH was excised from the fusion protein.
- the band at around 290 kDa is a fusion protein of MMI and AbH, a TCP tetramer of Siaguchinin subunit.
- a fusion protein expression system with daltathione-S-transferase (GST) pGEX-4T-1 vector B commercially available from Amersham Pharmaremacio Biotech
- the double-stranded DNA shown in SEQ ID NO: 34 was inserted into the amHI-NotI site, and the Spell site, HpaI site and 6His gene were introduced. Further, the MMI gene obtained in Example 8 was introduced between the BamHI site and the SpeI site.
- This expression vector was named pGEX MMI.
- Figure 17 shows the configuration of p GEX MMI. That is, pGEX MMI has a tac promoter, and a GST gene, an MMI gene, and a 6His gene are arranged downstream thereof in this order. Then, by inserting the gene of the target protein between the Spel site and the Hpal site, a vector that expresses a fusion protein of GST, MMI and the target protein can be constructed. 2. Expression and cleavage of GFP
- pI VEX2.3-GFP WT vector (Roche's Diagnostics) was used as type I, PCR was performed using the oligonucleotides shown in SEQ ID NOS: 23 and 24 as primers, and the GFP gene shown in SEQ ID NO: 25 was obtained. The containing DNA fragment was isolated. The DNA fragment was provided with an SpeI site at the 5 'end and an HpaI site at the 3' end, respectively, derived from the primers. This DNA fragment was inserted between the SpeI and HpaI sites of pGEXMMI constructed in this example. As a result, an expression vector pGEX MMI'GFP for synthesizing a fusion protein of GST, MMI and GFP was constructed. Similarly, an expression vector pGEXI ⁇ GFP into which the S spI gene prepared in Example 1 was introduced instead of the MMI gene was constructed.
- pGEX MMI • GFP (Example 10-1) and pGEX I-GFP (Example 10-1) were each introduced into E. coli BL21 (DE3) strain to obtain a transformant. These transformants were cultured in a 2XY.T. medium containing carbenicillin (100 ⁇ g / mL) at 25 ° C for 24 hours, and a fusion protein of GST, SspI and GFP, and GST The fusion protein of MMI and GFP was expressed. The cells were collected, suspended in 50 mM TrisZHCl buffer (pH 7.0), disrupted by sonication in the presence of a protease inhibitor cocktail, and centrifuged. The supernatant of the cell suspension was obtained.
- TrisZHCl buffer pH 7.0
- pGEXP was constructed in which a gene encoding a recognition sequence for precision protease was introduced between the BamHI site and the SpeI site instead of the gene encoding MMI. Then, except that pGEXP was used instead of pGEX MMI, the expression vector was constructed, transformed, and the transformant was cultured in the same manner as in Example 10. Got.
- Each of the bacterial cell lithotriptor night supernatants prepared in Example 10 and Comparative Example 10 was purified by Ni-NT A agarose gel (Qiagen) and treated at room temperature for 2 hours, and the histidine tag was added.
- Plasmid pETTPPPaseMMI in which the MMI gene was inserted in place of the SspI gene, from pETTPPPaseaseI prepared in Example 4, was constructed (FIG. 19).
- the DNA fragment containing the GFP gene shown in SEQ ID NO: 25 prepared in Example 10 was treated with SpeI and HpaI, and incorporated into an expression vector pETTPPIaseMMI treated with the same restriction enzymes.
- an expression vector pET TPPIase MMI • GFP for synthesizing a fusion protein of TPPIase, MMI and GFP was constructed.
- Cell-free protein expression (using Roche Diagnostics RTS 500) was performed on the resulting expression vector pET TPP ISE MMI 'GFP.
- PET TPP Iase I constructed in Example 4 was used (Comparative Example 11-1). Furthermore, pET TPP Iase P was constructed between the BamHI site and Spe I site of pET TPP Iase MMI, which is a gene encoding a recognition sequence of a precision protease instead of MMI (Comparative Example 11). I 2). Protein synthesis was carried out in the same manner as in Example 11 except that pET TPP Iase MMI • GFP was changed to pET TPP Iase I • 0 or pET TPP Iase P • GFP.
- Example 11 Each of the reaction solutions prepared in Example 11 and Comparative Example 11 was purified by Ni-NTA agarose gel (manufactured by QIAGEN) and treated at room temperature for 2 hours, and an anti-GFP mouse monoclonal antibody (Santa Cr) Perform estamplotting analysis using uz Biotec hnology) to determine whether GFP is cleaved from TPP Iase. The force was tested. The results are shown in FIG. In pET TPP Iase MMI • GFP of Example 11 (lane 3), GFP was observed at a molecular weight of around 27 kDa, confirming that GFP was cleaved from TPP Iase.
- the signal near 50 kDa is a fusion protein of TPPIas6, ⁇ : 1 ⁇ 1, and GFP.
- GFP was observed at a molecular weight of around 27 kDa, confirming that GFP was cleaved from TPP Iase.
- the signal around 62 kDa is a fusion protein of TPPIase, SspI and GFP.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004569240A JPWO2004096860A1 (ja) | 2003-04-28 | 2004-04-28 | 目的蛋白質の製造方法、融合蛋白質及びその遺伝子、インテインの部分配列蛋白質及びその遺伝子、発現ベクター、並びに形質転換体 |
US10/554,751 US20070092937A1 (en) | 2003-04-28 | 2004-04-28 | Method of producing target protein, fusion protein and gene thereof, protein consisting of partial sequence of intein and gene thereof, expression vector, and transformant |
AU2004234283A AU2004234283A1 (en) | 2003-04-28 | 2004-04-28 | Method of producing target protein, fused protein and gene thereof, partial sequence protein of intein and gene thereof, expression vector and transformant |
EP04730018A EP1621556A4 (en) | 2003-04-28 | 2004-04-28 | METHOD FOR PRODUCING TARGET PROTEIN, FUSED PROTEIN AND GENE, INTEIN PARTIAL SEQUENCE PROTEIN AND GENE, EXPRESSION VECTOR AND TRANSFORMANT |
CA002523034A CA2523034A1 (en) | 2003-04-28 | 2004-04-28 | Method of producing target protein, fused protein and gene thereof, partial sequence protein of intein and gene thereof, expression vector and transformant |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-124355 | 2003-04-28 | ||
JP2003-124354 | 2003-04-28 | ||
JP2003124354 | 2003-04-28 | ||
JP2003124355 | 2003-04-28 | ||
JP2003-421442 | 2003-12-18 | ||
JP2003421443 | 2003-12-18 | ||
JP2003-421443 | 2003-12-18 | ||
JP2003421442 | 2003-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004096860A1 true WO2004096860A1 (ja) | 2004-11-11 |
Family
ID=33425418
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/006191 WO2004096860A1 (ja) | 2003-04-28 | 2004-04-28 | 目的蛋白質の製造方法、融合蛋白質及びその遺伝子、インテインの部分配列蛋白質及びその遺伝子、発現ベクター、並びに形質転換体 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20070092937A1 (ja) |
EP (1) | EP1621556A4 (ja) |
JP (1) | JPWO2004096860A1 (ja) |
AU (1) | AU2004234283A1 (ja) |
CA (1) | CA2523034A1 (ja) |
WO (1) | WO2004096860A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100334216C (zh) * | 2004-11-16 | 2007-08-29 | 南京大学 | 一种在大肠杆菌中生产可溶性重组蛋白质的方法及其应用 |
US8349807B2 (en) | 2004-10-15 | 2013-01-08 | Joe Chiba | Method of immunizing animal, composition for immunization, method for producing antibody, method for producing hybridoma and method for producing monoclonal antibody |
CN116731126A (zh) * | 2023-01-30 | 2023-09-12 | 态创生物科技(广州)有限公司 | 内含肽ChiATP、内含肽ChiATP-二肽-2融合蛋白及二肽-2的表达方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1884517B (zh) | 2006-06-08 | 2010-06-30 | 武汉禾元生物科技有限公司 | 利用谷物非储藏蛋白为融合载体在胚乳表达多肽的方法及应用 |
WO2013045632A1 (en) * | 2011-09-28 | 2013-04-04 | Era Biotech, S.A. | Split inteins and uses thereof |
CN115074340B (zh) * | 2022-06-17 | 2023-02-28 | 广州市乾相生物科技有限公司 | 一种新内含肽及其在合成人源原弹性蛋白上的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1175879A (ja) * | 1997-07-08 | 1999-03-23 | Toyota Central Res & Dev Lab Inc | プロテインジスルフィドイソメラーゼを含有する融合タンパク質をコードするdna |
WO2002052029A1 (fr) * | 2000-12-26 | 2002-07-04 | Sekisui Chemical Co., Ltd. | Methode permettant de produire une proteine de recombinaison et une proteine fusionnee |
JP2003501064A (ja) * | 1999-06-09 | 2003-01-14 | メディカル リサーチ カウンシル | シャペロンポリペプチドのフラグメントを含む融合タンパク質 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1151117B1 (en) * | 1999-02-12 | 2008-10-15 | New England Biolabs, Inc. | Intein-mediated protein ligation of expressed proteins |
-
2004
- 2004-04-28 WO PCT/JP2004/006191 patent/WO2004096860A1/ja active Application Filing
- 2004-04-28 CA CA002523034A patent/CA2523034A1/en not_active Abandoned
- 2004-04-28 JP JP2004569240A patent/JPWO2004096860A1/ja not_active Withdrawn
- 2004-04-28 US US10/554,751 patent/US20070092937A1/en not_active Abandoned
- 2004-04-28 EP EP04730018A patent/EP1621556A4/en not_active Withdrawn
- 2004-04-28 AU AU2004234283A patent/AU2004234283A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1175879A (ja) * | 1997-07-08 | 1999-03-23 | Toyota Central Res & Dev Lab Inc | プロテインジスルフィドイソメラーゼを含有する融合タンパク質をコードするdna |
JP2003501064A (ja) * | 1999-06-09 | 2003-01-14 | メディカル リサーチ カウンシル | シャペロンポリペプチドのフラグメントを含む融合タンパク質 |
WO2002052029A1 (fr) * | 2000-12-26 | 2002-07-04 | Sekisui Chemical Co., Ltd. | Methode permettant de produire une proteine de recombinaison et une proteine fusionnee |
Non-Patent Citations (5)
Title |
---|
MATHYS S. ET AL: "Characterization of a self-splicing mini-intein and its conversion into autocatalytic N- and C-terminal cleavage elements: facile production of protein building blocks for protein ligation", GENE, vol. 231, no. 1-2, 1999, pages 1 - 13, XP004166772 * |
PERLER F.B. ET AL: "InBase: the Intein Database", NUCLEIC ACIDS RES., vol. 30, no. 1, 2002, pages 383 - 384, XP002972669 * |
See also references of EP1621556A4 * |
WU H. ET AL: "Protein trans-splicing and functional mini-inteins of a cyanobacterial dnaB intein", BIOCHIM. BIOPHYS. ACTA, vol. 1387, no. 1-2, 1998, pages 422 - 432, XP004278497 * |
ZHANG A. ET AL: "Construction of a mini-intein fusion system to allow both direct monitoring of soluble protein expression and rapid purification of target proteins", GENE, vol. 275, no. 2, 2001, pages 241 - 252, XP004307847 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8349807B2 (en) | 2004-10-15 | 2013-01-08 | Joe Chiba | Method of immunizing animal, composition for immunization, method for producing antibody, method for producing hybridoma and method for producing monoclonal antibody |
US8901099B2 (en) | 2004-10-15 | 2014-12-02 | Sekisui Chemical Co., Ltd. | Method for immunizing animal, composition for immunization, method for producing antibody, method for producing hybridoma, and method for producing monoclonal antibody |
CN100334216C (zh) * | 2004-11-16 | 2007-08-29 | 南京大学 | 一种在大肠杆菌中生产可溶性重组蛋白质的方法及其应用 |
CN116731126A (zh) * | 2023-01-30 | 2023-09-12 | 态创生物科技(广州)有限公司 | 内含肽ChiATP、内含肽ChiATP-二肽-2融合蛋白及二肽-2的表达方法 |
CN116731126B (zh) * | 2023-01-30 | 2024-02-23 | 态创生物科技(广州)有限公司 | 内含肽ChiATP、内含肽ChiATP-二肽-2融合蛋白及二肽-2的表达方法 |
Also Published As
Publication number | Publication date |
---|---|
US20070092937A1 (en) | 2007-04-26 |
CA2523034A1 (en) | 2004-11-11 |
AU2004234283A1 (en) | 2004-11-11 |
EP1621556A1 (en) | 2006-02-01 |
EP1621556A4 (en) | 2006-08-23 |
JPWO2004096860A1 (ja) | 2006-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5389882B2 (ja) | Dnaインサート増殖およびファージディスプレイ法のためのタンパク質発現の切り離し | |
US7271256B2 (en) | Method for producing circular or multimeric protein species in vivo or in vitro and related methods | |
EP1183346B1 (en) | Method for generating split, non-transferable genes that are able to express an active protein product | |
JP5469786B2 (ja) | タンパク質の発現増強および精製の方法および組成 | |
JP4038555B2 (ja) | 組み換え蛋白質の生産方法及び融合蛋白質 | |
US6858775B1 (en) | Method for generating split, non-transferable genes that are able to express an active protein product | |
AU2004234282B2 (en) | Chaperonine-target protein complex, method of producing the same, method of stabilizing target protein, method of immobilizing target protein, method of analyzing the structure of target protein, sustained-release preparation and method of producing antibody against target protein | |
WO2004096860A1 (ja) | 目的蛋白質の製造方法、融合蛋白質及びその遺伝子、インテインの部分配列蛋白質及びその遺伝子、発現ベクター、並びに形質転換体 | |
Zábranský et al. | Identification of a minimal HIV-1 gag domain sufficient for self-association | |
Jong et al. | Mutagenesis-based characterization and improvement of a novel inclusion body tag | |
JP2016518855A (ja) | 融合プロテアーゼ | |
Chan et al. | Construction of inducible expression vector pDNLS-22n containing P. aeruginosa PAO1 ChiC | |
Tosarini et al. | Cloning, expression and purification of kinase domains of cacao PR-1 receptor-like kinases | |
KR101119231B1 (ko) | Ραs 변이체 및 이를 포함하는 벡터 | |
JP2019527560A (ja) | リポタンパク質搬出シグナルおよびその使用 | |
KR102014901B1 (ko) | 단백질에 대한 나노운반체로서의 순도 및 안정성이 증진된 바이러스 유사 입자의 제조방법 | |
JPWO2004031243A1 (ja) | タンパク質ポリマー及びその製造方法 | |
Rial et al. | Chloroplast Hsp70s are not involved in the import of ferredoxin‐NADP+ reductase precursor | |
Möhrle | Nanobody selection from a highly variable gene library using mRNA/cDNA display | |
JP4918582B2 (ja) | グルクロン酸転移酵素の製造方法 | |
WO2024126847A1 (en) | Mrna recombinant capping enzymes | |
Pham | Characterization of a tryptophanyl-tRNA synthetase urzyme and its intramolecular complementation establishes a model to study the catalytic mechanism and evolution of the contemporary class I aminoacyl-tRNA synthetases | |
JP2006111572A (ja) | シャペロニン−タンパク質複合体及びその製造方法、並びに目的タンパク質の製造方法 | |
Müller et al. | Promiscuous targeting of polytopic membrane proteins to SecYEG or YidC by the E. coli Signal Recognition Particle Thomas Welte*,||, Renuka Kudva*,†,‡,||, Patrick Kuhn*,†, Lukas Sturm*, David Braig | |
Wang | Halifax, Nova Scotia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2004569240 Country of ref document: JP |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2523034 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004234283 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007092937 Country of ref document: US Ref document number: 10554751 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2004234283 Country of ref document: AU Date of ref document: 20040428 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004730018 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004234283 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004730018 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10554751 Country of ref document: US |